# Title: Quantitatively assessing early detection strategies for mitigating COVID-19 and future pandemics

Authors: Andrew Bo Liu<sup>1,2</sup>\*, Daniel Lee<sup>2,3</sup>, Amogh Prabhav Jalihal<sup>1</sup>, William P. Hanage<sup>4</sup>,
 Michael Springer<sup>1</sup>\*

- <sup>5</sup> <sup>1</sup> Department of Systems Biology, Harvard Medical School; Boston, MA, USA.
- 6 <sup>2</sup> Department of Biomedical Informatics, Harvard Medical School; Boston, MA, USA.
- <sup>3</sup> Program in Medical and Population Genetics, Broad Institute of MIT and Harvard; Cambridge,
   MA, USA.
- <sup>9</sup> <sup>4</sup> Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H.
- 10 Chan School of Public Health; Boston, MA, USA
- 11 \* Corresponding author(s). Email(s): andrewliu@g.harvard.edu (A.B.L.);
- 12 michael\_springer@hms.harvard.edu (M.S.).
- 13 Abstract: Researchers and policymakers have proposed systems to detect novel pathogens
- 14 earlier than existing surveillance systems by monitoring samples from hospital patients,
- 15 wastewater, and air travel, in order to mitigate future pandemics. How much benefit would such
- 16 systems offer? We developed, empirically validated, and mathematically characterized a
- 17 quantitative model that simulates disease spread and detection time for any given disease and
- 18 detection system. We find that hospital monitoring could have detected COVID-19 in Wuhan 0.4
- 19 weeks earlier than it was actually discovered, at 2,300 cases (standard error: 76 cases) compared
- 20 to 3,400 (standard error: 161 cases). Wastewater monitoring would not have accelerated COVID-
- 21 19 detection in Wuhan, but provides benefit in smaller catchments and for asymptomatic or long-
- 22 incubation diseases like polio or HIV/AIDS. Monitoring of air travel provides little benefit in
- 23 most scenarios we evaluated. In sum, early detection systems can substantially mitigate some
- future pandemics, but would not have changed the course of COVID-19.

25

#### 26 Introduction

27 It has been widely debated which policies, if any, could have mitigated the health impacts of the

- 28 initial stages of the COVID-19 pandemic in late 2019 and early 2020 as community transmission
- became established and widespread. Early studies compared non-pharmaceutical interventions 29
- (NPIs) such as mobility restrictions<sup>1,2</sup>, school closures<sup>3,4</sup>, voluntary home quarantine<sup>5</sup> and testing 30
- policies<sup>6</sup>, and optimized NPI parameters like testing frequency<sup>7</sup>, quarantine length<sup>8</sup>, testing 31
- modality<sup>9</sup>, test pooling<sup>10</sup> and intervention timing and ordering<sup>11</sup>. While such NPIs undoubtedly slowed the early spread of COVID-19<sup>12</sup> and previous outbreaks<sup>13,14</sup>, there has been little 32
- 33 investigation of whether a separate strategy focused on earlier detection of COVID-19 would 34
- 35 have enabled more successful mitigation. In theory, earlier detection enables a response when the
- 36 outbreak is smaller: thus, resource-intensive mitigation strategies like test-trace-isolate become
- 37 less costly, and the earlier interventions are applied, the larger the number of infections and
- 38 deaths that can be delayed until healthcare capacity is increased<sup>15</sup>. However, the relevant
- 39 question is not whether early detection helps, but quantitatively how much of a difference it
- 40 would make. This question is especially urgent given current international and national policy
- proposals to invest billions of dollars in such systems<sup>16,17</sup>. 41
- Researchers and policymakers have proposed immediate investments in systems to continuously 42
- monitor for novel pathogens in (i) patients with infectious symptoms in hospitals and clinics<sup>18,19</sup> 43
- 44
- (ii) community wastewater treatment plants<sup>20,21</sup>, and (iii) airplane sewage or bridge air on international flights<sup>22–24</sup>, as well as other sites<sup>25–29</sup>. These three sites have attracted interest 45
- because they have been frequent testing sites in COVID-19: hospitals since the pandemic's 46
- beginning<sup>30</sup>, and wastewater (including wastewater at treatment plants<sup>20</sup>, within the sewershed<sup>31</sup>, 47
- and locally near individual buildings<sup>32</sup>) and air travel more recently<sup>33,34</sup> because hospital cases 48
- can lag community cases<sup>35</sup>. COVID-19 also spurred methodological innovation and 49
- characterization of sampling from these sites<sup>36</sup>, particularly wastewater<sup>37–39</sup>. Detecting novel 50 pandemics at these sites has occasionally been piloted<sup>21,40</sup> but has not been implemented at scale, 51
- in part because it is unclear if these proposed systems sufficiently expedite detection of 52
- 53 outbreaks. The systems under consideration would use multiplex testing for conserved nucleic
- 54 acid sequences of known pathogen families, exploiting the fact that many past emerging diseases
- belonged to such families, including SARS-CoV-2 (2019), Ebola (2013), MERS-CoV (2012), 55
- and pandemic flu (2009). Proposed technologies include multiplex PCR<sup>41–44</sup>, CRISPR-based 56
- multiplex diagnostics<sup>45</sup>, and metagenomic sequencing<sup>46</sup>, possibly implemented with pooling<sup>10</sup>. 57
- 58 To determine whether early detection of novel pathogens at these sites could be effective in
- 59 changing the course of a pandemic, we first examined whether COVID-19 could have been
- 60 detected earlier in Wuhan if systems had been in place in advance to monitor hospitals,
- 61 wastewater or air travel. To do this, we developed, empirically validated, and mathematically
- 62 characterized a simulation-based model that predicts the number of cases at the time of detection
- given a detection system and a set of outbreak epidemiological parameters. We then used this 63
- model and COVID-19 epidemiological parameters<sup>47</sup> to estimate how early COVID-19 would 64
- initially have been detected in Wuhan by the three early detection systems, and compare this to 65
- the actual date of COVID-19 detection. Finally, we use our model to estimate detection times of 66
- 67 infectious agents with different epidemiological properties, such as mpox and polio in recent
- outbreaks<sup>48,49</sup>, to inform pathogen-agnostic surveillance for future pandemics. 68
- 69 **Results**


#### 70 Model to estimate earliness of detection

Previous research<sup>15</sup> and our analysis (Supplementary text, figs. S1-5 and table S1) suggest that 71 72 earlier COVID-19 lockdowns could have delayed cases and deaths. Thus, it is critical to 73 understand which early detection systems, if any, could have effectively enabled earlier 74 response. To do this, we built a model that simulates outbreak spread and earliness of detection 75 for a given outbreak and detection system (Materials and methods, Supplementary materials). 76 This builds upon branching process models that have previously been used to model the spread of COVID-19<sup>50,51</sup> and other infectious diseases<sup>52</sup>. A traditional branching process model starts 77 78 from an index case and iteratively simulates each new generation of infections. Our model 79 follows this pattern, but with each new infection we also simulate whether the infected person is 80 detected by the detection system with some probability (Fig. 1A), and the simulation stops when 81 the number of detected individuals equals the detection threshold and the detection delay has 82 passed. Thus, each detection system is characterized by these three parameters of detection 83 probability, threshold, and delay (table S2). For example, in hospital monitoring, an infected 84 individual's detection probability is the probability they are sick enough to enter the hospital, which is the hospitalization rate (assuming testing has a negligible false negative rate). In 85 systems that test individuals (hospital and air travel individual monitoring), the threshold is 86 87 measured in an absolute number of cases. In systems that test wastewater (wastewater 88 monitoring), the threshold is measured in terms of outbreak prevalence because wastewater 89 monitoring can only sample a small percentage of sewage flows, depending on the sampling 90 capacity<sup>53</sup>; thus, a higher number of cases is required to trigger detection in a bigger community 91 (Materials and methods). We gathered literature estimates of detection system and outbreak 92 parameters (tables S2 and S3) and validated wastewater monitoring sensitivity in independent 93 data (fig. S6 and Materials and methods, Supplementary materials). We then empirically validated the model by testing its ability to predict the detection times for the first COVID-19 94 95 outbreaks in 50 US states in 2020. We gathered the dates of the first COVID-19 case reported by the public health department of each US state (table S4) as well as literature estimates of true 96 (tested and untested) statewide COVID-19 case counts in early 2020<sup>54</sup>. Using our model, we 97 98 were able to predict the number of weeks until travel-based detection in each US state to within a 99 mean absolute error of 0.97 weeks (fig. S7 and S8). To check the robustness of our results, we 100 implemented a second, more complex model with varying reproduction number using a Monte Carlo simulation-based package (EpiNow2<sup>55</sup>). A list of model assumptions can be found in table 101 102 S5.

#### 103 Early detection's impact on COVID-19 detection in Wuhan

104 Next we use our model to examine the detection systems' ability to detect the first major 105 COVID-19 outbreak in Wuhan (Fig. 1B and table S2). To estimate cases at detection in the 106 actual pandemic, we used literature estimates of total (tested and untested) COVID-19 case 107 counts in Wuhan in late 2019 and early  $2020^{56}$ . Our model shows that, on average, hospital monitoring could have detected COVID-19 after 2,292 cases (standard error: 76 cases). In 108 109 reality, the pandemic was identified after 3,413 cases on average (standard error: 161 cases). 110 Thus, hospital monitoring would have caught the outbreak 1,121 cases earlier (approximately 111 0.43 weeks earlier), a statistically significant difference with p = 1.9e-09 and t = -6.3 (df = 141) 112 in a one-sided Welch two-sample t-test. Wastewater monitoring would have lagged detection in 113 the actual pandemic; it caught the outbreak after 4,575 cases (standard error: 523 cases), or 1,162 114 cases later, on average (p = 0.018; t = 2.1; df = 118). We tested this wastewater prediction

- empirically by calculating the cases until COVID-19 wastewater detection in Massachusetts in
- early 2020, using literature-estimated Massachusetts COVID-19 cases<sup>54</sup> and Massachusetts
- 117 wastewater SARS-CoV-2 PCR data<sup>57</sup>; our model prediction was consistent with this analysis
- 118 (fig. S9). Because we model wastewater monitoring to detect later in larger communities
- 119 (Materials and methods, Supplementary materials), the Wuhan result is in part due to Wuhan's
- 120 650,000-person catchments. Wastewater monitoring would lead status quo detection of COVID-
- 121 19 in catchments smaller than 480,000 people, well above the global mean catchment size of
- 122 25,000 people<sup>58</sup>. Air travel monitoring did not provide any acceleration of detection because of
- 123 the low probability of simultaneously traveling and being sick.



124

125 Fig. 1. Comparison of COVID-19 detection times in the actual pandemic versus with

126 proposed early detection systems. (A) Schematic of first 20 infections in a simulated run of the

detection model. In this run, Person 1 seeds an outbreak in a community covered by a hospital

128 detection system. Each person infects a number of individuals determined by a draw from a

- negative binomial distribution. Each person is then detected by the detection system with
- 130 probability  $p_{test}$  (gold) or goes undetected (olive); in the hospital system,  $p_{test}$  equals the
- 131 hospitalization rate. (B) Estimated cases until COVID-19 detection in the actual pandemic versus
- 132 model-simulated cases until detection for proposed detection systems (center line, median; box
- 133 limits, upper and lower quartiles; whiskers, point closest to 1.5x interquartile range). Estimates
- 134 for the actual pandemic are drawn from  $5^{6}$ . Points for proposed detection systems are simulated
- 135 case counts from the model (actual pandemic (black), hospital (teal), wastewater (orange) and air
- travel (purple)) assuming a Wuhan-sized catchment (650,000 people). Three, two, and one
- 137 asterisk(s) signify that the cases upon detection for the detection system are statistically
- 138 significantly lower than those in the actual pandemic at the 0.001, 0.01, and 0.05 levels,
- respectively, in one-sided t-tests. NS. signifies not statistically significantly lower at p=0.05.
- 140 Equivalent weeks until detection are shown on the right y-axis.
- 141 Early detection's impact for other diseases: mathematical analysis and simulation
- 142 To make our model easily usable for pathogenic outbreaks beyond COVID-19, we derived a
- 143 compact formula that approximates the model's simulations. We observed that, without
- 144 accounting for the delay of g generations between the threshold case's infection and detection,
- 145 the number of cases until detection, *C*, is a random variable that follows a negative binomial
- 146 distribution by definition: each infected case is a Bernoulli trial, "success" in that trial occurs
- 147 when that case enters the detection system (with a probability we name  $p_{test}$ ), and we count the
- 148 number of cases until the number of successes equals the detection threshold d. After accounting
- 149 for g and the basic reproduction number  $R_0$ , we derived a formula approximating the mean of C
- 150 when the outbreak starts in a community covered by the detection system (see Supplementary
- 151 Text for full derivation):

$$\mathbb{E}[C] \approx \frac{d \times R_0^g}{p_{test}} \quad (1)$$

152 We confirmed our formula approximates the simulation model closely by comparing the

detection times predicted by both for all the detection systems for multiple diseases (fig. S10).

154 Thus, the formula allows us to interpret the model and the quantitative relationships between

155 detection times and various variables: the formula shows that the number of cases until detection

156 increases linearly with the detection threshold, increases polynomially with  $R_0$  and exponentially

157 with the delay g as  $R_0^{g}$ , and decreases as the fraction of cases being tested increases. This

158 formula also makes the model easily usable for detection systems beyond the ones studied here.

159 We applied our model to several outbreaks of recent interest–including COVID-19, mpox

160 (2022), polio (2013-2014), Ebola (2013-2016) and flu (2009 pandemic)–and found that the

161 detection systems vary in their success depending on the epidemiological parameters of the agent

162 (Figs. 2, S11 and S12, and table S3). For example, in our model hospital monitoring tends to

163 outperform wastewater monitoring when the hospitalization rate is high, as in the case of Ebola,

but tends to underperform for diseases like polio, in which the hospitalization rate is low and


when there is high asymptomatic spread in the delay from detection to hospitalization. This is

166 consistent with Equation (1), as well as previous observations that Ebola was first detected in

hospitals<sup>59</sup> and that wastewater monitoring has been more effective than hospital monitoring for detecting polio<sup>60</sup>. We also modeled the status quo detection times for these outbreaks: the

number of cases until these outbreaks were detected in the status quo, without the proposed

- 170 detection systems in place. We found that early detection systems can catch outbreaks when they
- are up to 52% smaller (wastewater for polio) or 110 weeks earlier (hospital for HIV/AIDS) (figs.
- 172 S13, S14, S15 and S16). Similar results hold for the more complex model: the relative median
- 173 detection times of the three systems remain the same 97% of the time across the five main
- 174 diseases (29/30 pairwise comparisons) (fig. S17).




С

Diseases	COVID-19	Ebola (2013–2016)	Flu (2009 pandemic)	Mpox (2022)	Polio (2013–2014)
Hospitalization rate	0.03	0.72	0.01	0.03	0.01
R0	2.50	1.80	1.60	1.40	1.60
Serial interval (weeks)	1.00	2.10	0.30	1.40	0.60
Time to hospitalization (weeks)	1.50	2.30	0.50	2.00	1.60
Probability of fecal shedding	0.50	0.50	0.25	0.50	0.90
Dispersion	0.70	0.10	0.10	0.10	0.10

175

#### 176 Fig. 2. Comparison of detection systems for different infectious diseases. (A) Earliness of

- 177 detection for detection systems in cases across infectious diseases (hospital (teal), wastewater
- 178 (orange), air travel (purple) and status quo (black)) in a 650,000-person catchment (center line,
- 179 median; box limits, upper and lower quartiles; whiskers, point closest to 1.5x interquartile
- 180 range). (B) Earliness of detection for detection systems in weeks across infectious diseases in a
- 181 650,000-person catchment. (C) Epidemiological parameters of the studied diseases.
- 182 Because future infectious diseases are likely to have different epidemiological parameters, we
- 183 generalized the previous analysis and calculated detection times for many possible diseases
- 184 spanning the epidemiological parameter space (Figs. 3 and S18). As expected, hospital
- 185 monitoring is the best system for diseases with higher hospitalization rates and lower times to
- 186 hospitalization. For diseases with higher R0s and times to hospitalization, wastewater monitoring
- 187 emerges as the best system more often, because hospital monitoring has a longer detection delay
- 188 (mainly the time from infection to hospitalization) than wastewater (mainly the time from
- 189 infection to fecal shedding), during which cases grow exponentially with R0. However, this
- 190 holds mainly for diseases with high probability of fecal shedding and low hospitalization rate.
- 191 Air travel monitoring, which did not perform well in the previous modeled diseases (Figs. 1 and
- 192 2), actually performed best for a few diseases for which fecal shedding is low (disadvantaging
- 193 wastewater monitoring) and the time to hospitalization and R0 are too large (disadvantaging
- 194 hospital monitoring).



#### 196 Fig. 3. Comparison of detection systems across the space of possible diseases of varying

- epidemiological parameters. (A) Average weeks gained over status quo detection by the
- 198 proposed detection systems across the epidemiological space of possible diseases. Within each
- 199 panel, each uniformly colored cell corresponds to a specific disease with the hospitalization rate 200 and probability of fecal shedding indicated on the x- and y-axes, as well as the R0 and time to
- and probability of fecal shedding indicated on the x- and y-axes, as well as the R0 and time to hospitalization (generations) indicated by the panel row and column. The cell has a hue
- 202 corresponding to the detection system that detects the disease the earliest (hospital (teal),
- wastewater (orange) and air travel (purple)) and an intensity corresponding to the number of
- weeks gained by the earliest system over status quo detection. Times are calculated by the
- 205 derived mathematical approximation in a 650,000-person catchment.

#### 206 Discussion

- 207 Our results show that the benefits of early detection systems vary from marginal (0.4 weeks
- 208 earlier for COVID-19) to significant (110 weeks earlier for HIV/AIDS) (Figs. 1B, 2, and S16).
- 209 Our detection time model (Fig. 1A) can be used for many diseases and detection systems,
- 210 including other systems beyond this study $^{25,26}$ , by varying the fraction of the infected population
- 211 being tested in each system. Some further points are worth emphasizing. First, early detection
- only aids mitigation if it leads to a coordinated early response. Many factors beyond detection
- affect the pace of response, including the economic and political feasibility of lockdowns, the
- availability of medicines and personal protective equipment, and whether there are pre-
- 215 determined policies to be implemented upon detection. Second, when deciding to invest in these
- systems, one must consider factors such as cost-effectiveness and whether the system provides evidence of disease severity. Although wastewater monitoring gives earlier detection than
- hospital monitoring in multiple diseases (Fig. 3A), it does not discriminate between mild and
- severe disease (although sequencing could detect lineages known to cause severe illness). In
- 219 severe disease (almough sequencing could detect integes known to cause severe integs). In 220 contrast, hospital monitoring provides evidence that the detected pathogen produces symptoms
- that require hospital treatment. Third, our model is meant to be used now, in advance of future
- 222 pandemics, and not in the early months of a novel pandemic, because early detection systems
- must be set up in advance of the next pandemic to be effective. Because we do not know the
- 224 epidemiological parameters of the next pandemic, our study assesses how these systems would
- 225 perform for a wide, representative variety of diseases with different epidemiological parameters,
- in order to quantify these systems' benefits in general.
- 227 These results can inform ongoing international and national policy debates about which policies
- are needed to mitigate future pandemics. In the wake of COVID-19, the World Health
- 229 Organization Intergovernmental Negotiating Body is actively negotiating a new treaty on
- international pandemic preparedness which updates the International Health Regulations (2005).
- Drafts of this treaty highlight "early warning and alert systems" as key measures<sup>16</sup>. Similarly, the
- presidential administration of the United States has proposed investing \$5.3 billion over 7 to 10
- 233 years in early warning and real-time monitoring systems, including in hospitals and
- 234 wastewater<sup>17</sup>. In this study, we have assessed detection systems' detection times and have
- 235 developed a model to assess current and future detection system proposals. Along with additional
- 236 cost-effectiveness analysis and technical pilots<sup>21</sup>, these results can help inform which detection
- systems are most effective and thus worth funding in pandemic preparedness efforts.

## 238 Methods

#### 239 Description of model predicting cases at detection.

- 240 Our branching process-based model predicts the cumulative number of cases at the time of
- 241 detection for a given detection system and outbreak. It follows the approach of branching process
- simulation models used previously to model the spread of COVID-19<sup>50,51</sup> and other infectious
- 243 diseases<sup>52</sup>, but with the main added step of simulating each infected person's chance of being
- 244 detected by the detection system. The values for parameters for detection systems can be found
- in table S2. The values for epidemiological parameters for outbreaks (R0, serial interval,
- dispersion, hospitalization rate, and time to hospitalization) can be found in Fig. 2 and table S3.
- 247 As in previous models<sup>52</sup>, we assume the offspring distribution (the number of secondary cases
- 248 infected by each primary case) is negative binomial with mean R0.
- 249 We generally follow past detection system proposals<sup>19,21</sup> to determine the implementation details
- 250 of each system in our model. Our model assumes the following. In hospital monitoring, hospitals
- would test for high-priority pathogen families (e.g. coronaviruses) in patients presenting with
- 252 severe infectious symptoms in hospital emergency departments<sup>19</sup>. Similarly, in wastewater
- 253 monitoring, governments would test for pathogens in city wastewater treatment plants daily, and
- 254 monitor for high and increasing levels of high-priority pathogen families<sup>21</sup>. In air travel
- 255 monitoring, we model testing of individual symptomatic passengers (differs from proposals to  $\frac{22}{2}$
- 256 monitor airplane sewage<sup>22</sup> or bridge air) on incoming international flights for the same 257 moth evens. The perspectators of these systems are shown in table  $S^{22}$
- 257 pathogens. The parameters of these systems are shown in table S2.
- 258 Our model also accounts for different delays involved in different detection systems. For
- example, if the 500th case of a COVID-19-like outbreak triggers the detection threshold in both
- 260 the hospital and wastewater monitoring systems, because of the significant delay from infection
- to hospitalization compared to the delay from infection to fecal shedding, the wastewater system
- would catch the outbreak earlier.
- 263 In systems that test individuals (hospital and air travel individual monitoring), the threshold is
- 264 measured in an absolute *number* of cases. In systems that test wastewater (community and air
- travel wastewater monitoring), the threshold or sensitivity is measured in prevalence (cases as a
- 266 *percentage* of the population)<sup>53,61,62</sup>. To predict the number of cases and time to detection, we
- 267 need to convert this percentage back to a number of cases, so the wastewater detection time
- 268 depends on the catchment population size.
- 269 To estimate wastewater sensitivity measured in prevalence, we used data from  $5^{53}$ .  $5^{53}$  conducted
- 270 PCR testing for SARS-CoV-2 1687 longitudinal wastewater samples from 353 sampling
- 271 locations in 40 US states in early 2020, and synced these with publicly reported local daily new
- 272 COVID-19 case counts. This enables us to estimate a distribution of the wastewater sensitivity:
- the lowest case count required to trigger positive detection in wastewater. Of the 353 sampling
- locations, 47 had both SARS-CoV-2-positive and negative samples such that local case counts
- on days of positive samples were all higher than those on days of negative samples. We thus
- knew each sampling location's sensitivity is between the maximum of case counts on negative
- sample days and the minimum of case counts on positive sample days. We took the midpoint of this maximum and minimum as the location's sensitivity; this gave us 47 local sensitivities. We
- fitted this to a log-normal distribution with a median of 2.5 daily new cases per 100,000 people.
- As expected, this distribution is similarly shaped but slightly left-shifted of the distribution in

Figure 2b of  $^{53}$  (median 3.7 per 100,000), because the latter distribution is an upper bound of the former.

283 To use this distribution in our model, in each simulation run, we first randomly drew a 284 wastewater sensitivity from this distribution, and then we needed to convert this *reported* 285 incidence i to the true (reported and unreported) number of cases shedding fecally into public 286 wastewater systems up to the time of wastewater detection. We converted as follows. Let day T 287 be the day on which the incidence *i* is reported. First we assumed the wastewater SARS-CoV-2 288 level on day T is proportional to the number of COVID-19 cases who are fecally shedding on 289 day T, which we estimate as the number of fecal shedders infected 2 days before, given the dominant peak in fecal shedding on day 2 of infection<sup>61</sup>. We infer the number of fecal shedders 290 291 infected on day T-2 from the incidence as follows. To account for underreporting, we first 292 estimate a true daily incidence of 5.7 x i with symptom onset on day T, based on estimates of the ratio of true (dated by symptom onset) to reported (dated by reporting date) COVID-19 cases in 293 the United States in early 2020<sup>54</sup>. (This study's abstract reports true cases are 5-50x reported 294 295 ones, but this refers to the early March 1-April 4, 2020, period. We calculated the factor of 5.7 296 from the study's data when we use the fuller March 1-May 16 period, which overlaps better with 297 the February-June 2020 period in<sup>53</sup> and reflects less underreporting as the pandemic developed 298 and testing capacity increased. We calculated this underreporting factor as an average of state-299 level underreporting factors, weighted by frequency of each state among the wastewater samples 300 in<sup>53</sup>.) Finally, we multiply by (a) the fraction of cases who shed fecally  $(0.5^{63})$  and (b) the fraction of people connected to central sewage (0.8 in the US<sup>64</sup>, which is the area from which 301 the<sup>53</sup> threshold is derived). This gives us the one-time prevalence of cases p who contribute to the 302 303 wastewater SARS-CoV-2 level on day T. For a given catchment with population c, this one-time number of cases is cp, and we estimate the cumulative number of fecal shedders up to this time 304 as  $\sum_{t=T}^{0} \frac{cp}{R_0^{t/7}} \approx \int_{t=0}^{T} \bar{R}_0^{t/7}$ , where  $T = \log_{R_0^{t/7}} (cp)$  is the number of days for the daily exponential 305

306 outbreak incidence curve to grow from 1 to *cp* cases.

To check this estimate, we identified studies that compared wastewater and hospital COVID-19 trends<sup>20,53</sup>.<sup>20</sup> found that trends in wastewater SARS-CoV-2 values led trends in hospital

- 309 admissions by 1-4 days in New Haven (catchment size 2e+05). We estimate that wastewater
- detection would lead hospital detection of COVID-19 in New Haven by -0.8 to 3 weeks (90%
- CI). This is consistent with the 1-4d lead estimate from<sup>20</sup>. Similarly,<sup>53</sup> found that trends in
- wastewater led those in clinical data by 4 days in Massachusetts (catchment size 2,300,000).
- Their clinical data are dated by date of reporting rather than sample gathering; assuming that
- hospital admissions are 5 days ahead of tests by date of reporting<sup>20</sup>, then wastewater is 5d-4d=1
- 315 day behind hospital admissions. We estimate that wastewater detection would lead hospital
- detection of COVID-19 in Massachusetts by -4 to -0.09 weeks (90% CI). This is consistent with
- 317 the 1-day lag estimate from  $5^{3}$ .
- 318 <u>Validation of model in US states.</u>
- 319 We gathered two sources of data for each state: dates of COVID-19 detection and COVID-19
- 320 case counts in early 2020. For the former, we searched media reports and US state public health
- 321 press releases to determine the dates of the first COVID-19 case reported in each US state.
- 322 Sources for each state's detection date are listed in table S4. We were able to identify such dates
- for all 50 states.

- For the latter, we used literature estimates of true (tested and untested) COVID-19 case counts,
- 325 which incorporate COVID-19 mortality data to deal with variation in testing capacity among
- 326 states<sup>54</sup>. We received a time series of weekly symptomatic COVID-19 case estimates for March
- 1-May 10, 2020 and divided by a symptomatic rate of 0.55 to get an estimate of total
- 328 (symptomatic and asymptomatic) cases<sup>47</sup>. We specifically used estimates from the adjusted
- 329 mMAP (mortality maximum a posteriori) method because<sup>54</sup> had mMAP estimates for all 50
- 330 states, whereas other methods from the same study were missing estimates for various states. We
- fit an exponential curve of case counts in each state to extrapolate cases back to January 2020. In
- the data we received, all states had case data for all weeks in March 1-May 10, 2020.
- 333 We used our model to predict the weeks until detection in each US state (y-axis in Fig. S7).
- Because most US states detected their first case by travel (table S4), we modeled a travel-based
- detection system similarly to how we modeled the aforementioned detection systems. We
- simulated a growing stream of imported travel cases ( $R0^i$  cases for the *i*-th generation and global
- R0 = 2.5), and as for the other detection systems, we simulated infection and detection steps for
- each generation, except that we only allowed travel-associated cases to be detected. We assumed
- that the state COVID-19 outbreaks had the same values for all epidemiological parameters
- except for R0, which we allowed to vary by state to account for state-specific conditions. We obtained state-specific R0 values from  $^{65}$ . The values for shared parameters were obtained from
- obtained state-specific R0 values from<sup>65</sup>. The values for shared parameters were obtained from
   literature (table S3). We used a detection delay of 12 days (5-day incubation period<sup>47</sup> plus 7-day
- $12 \text{ test and reporting turnaround in early 2020 in the US<sup>66</sup>) because many first cases were detected$
- following symptoms. The only parameter we were unable to precisely estimate from literature
- was the probability of a travel case being detected. We noted that this rate was at most the
- 346 COVID-19 symptomatic rate  $(0.55^{47})$  and at least the hospitalization rate  $(0.03^{47})$ : in the highest-
- 347 detecting scenario, every symptomatic case would volunteer to be tested; in the lowest-detecting
- 348 scenario, only hospitalized travel cases would get flagged for testing. So we chose a rate of 0.1,
- near the two rates' geometric mean. The predicted detection time for each state (the y-value reported in Fig. S7) was the mean of 100 simulations
- reported in Fig. S7) was the mean of 100 simulations.
- We compared these predictions to ground truth estimates in each state (x-axis in Fig. S7). These ground truth estimates were calculated by summing the aforementioned weekly case counts from
- ground truth estimates were calculated by summing the aforementioned weeklythe first week of January 2020 until the date of detection in that state (Fig. S8).
- 354 <u>Comparison of COVID-19 detection times in the actual pandemic versus with proposed early</u>
   355 <u>detection systems.</u>
- 356 We used our model to examine whether the early detection systems could have detected COVID-
- 357 19 earlier than in the actual pandemic. To do this, we used two data sources: (1) literature
- 358 estimates of total (tested and untested) COVID-19 case counts in late 2019 and early 2020<sup>56</sup> and
- 359 (2) simulation output from our model. We then used (1) to calculate the cumulative number of
- 360 cases when COVID-19 was actually detected, and compared this to results from (2).
- 361 For (1), we chose to use estimates from  $^{56}$ , which quantifies both the time of SARS-CoV-2
- 362 introduction into humans and the time series of cases following said introduction. These
- 363 estimates are based on phylodynamic rooting methods applied to SARS-CoV-2 sequence data,
- 364 combined with epidemic simulations and accounting for epidemiological data on the first known
- 365 cases of COVID-19. These estimates improve upon previous attempts to time SARS-CoV-2's

- introduction into humans, which are solely based on phylodynamic rooting methods to quantify the time to the most recent common of SABS CoV 2 common  $20^{57}$
- 367 the time to the most recent common ancestor of SARS-CoV-2 sequences<sup>67</sup>.
- 368 As instructed by  $5^{56}$ , we utilized
- 369 'BEAST.primary.IH.Dec10\_16.linB.Dec15\_25.linA.cumulativeInfections.timedGEMF\_combine
- d.stats.pickle' from GitHub<sup>68</sup> to obtain the distribution of daily case counts. Conditioning on the
- fact that there were at least six COVID-19-related hospitalizations by 2019-12-29<sup>69</sup>, we
- arrowed the distribution to those epidemic simulations with the top 25 percent of
- 373 hospitalizations and case counts. We simulated 100 draws from this distribution, and then took
- the number of cases on 2019-12-29 in each simulation to get 100 values for the distribution of
- 375 cumulative cases at detection in the actual pandemic ('Actual pandemic' boxplot in Fig. 1B). We
- 376 chose 2019-12-29 as the date that COVID-19 was detected in the actual pandemic, because this
- 377 was the date of the first report of an outbreak of pneumonia cases to health authorities in  $\frac{278}{1000}$  Wuhen<sup>70</sup>
- $378 \qquad \text{Wuhan}^{70}.$
- For (2), we ran our model for COVID-19 (see table S3 for the epidemiological parameters used)
- and all three detection systems (100 simulations for each system). For each detection system, this
- 381 gave us the estimated number of cases until detection of COVID-19 if that system had been in
- 382 place at the start of the pandemic. We assumed the system was present in the community in
- 383 which COVID-19 originated. We compared each system to the actual pandemic, and determined 384 that detection could have occurred earlier with the system if there was a statistically significant
- difference in cases until detection between the actual pandemic and the simulated world with the
- system (Fig. 1B). Statistical significance was assessed by a 1-sided t-test in which the alternative
- 387 hypothesis was that the detection system performed better.
- 388 We could empirically test our model predictions for the cases until wastewater detection by using
- 389 literature-estimated total COVID-19 cases in Massachusetts<sup>54</sup> and Massachusetts wastewater
- 390 SARS-CoV-2 data<sup>57</sup> in early 2020. We aimed to use these to estimate the cases until COVID-19
- 391 wastewater detection in Massachusetts in early 2020, but because Massachusetts wastewater
- 392 sampling for COVID-19 started only after the Massachusetts outbreak was underway,
- 393 wastewater samples were positive for SARS-CoV-2 on the first day of testing, so this first day of
- testing was later than when wastewater detection could have caught SARS-CoV-2 if wastewater
- detection had been in place in advance. Thus, we could only calculate an upper bound on the true
- cases until detection. We utilized the wastewater time series from the Massachusetts Water
- Resources Authority (MWRA) website and synced it with the COVID-19 case count time series
- 398 (Fig. S9). We multiplied the Massachusetts statewide cases by 0.33 (equal to
- 399 2,300,000/6,900,000) because the MWRA data covers 2,300,000 people, out of 6,900,000 people
- in Massachusetts in 2020. We then summed these case counts up to the date of apparent
- 401 wastewater detection to get an upper bound for cases at detection, and checked whether our
- 402 model prediction was consistent with this bound.
- 403 <u>Model-simulated cases required to trigger COVID-19 detection versus mathematical</u>
   404 <u>approximations.</u>
- 405 We compared the model simulations of cases until detection with our derived mathematical
- 406 formula, Equation (1) (Fig. S10). The points in Fig. S10 are the same as in Fig. 2A. The dashed
- 407 lines are generated by plugging values into Equation (1) for each detection system: we plugged

- 408 in the detection threshold, detection probability, outbreak R0, and detection delay (measured in
- 409 number of generations, i.e. serial intervals) for d,  $p_{test}$ , R0, and g, respectively.
- 410 <u>Comparison of detection systems for different infectious diseases.</u>
- 411 We applied our model to several outbreaks of recent interest: COVID-19, mpox (2022), polio
- 412 (2013-2014), Ebola (2013-2016) and flu (2009 pandemic) (Fig. 2A). Because of the lack of data
- 413 on the number of cases at the time of detection in previous outbreaks (except for the COVID-19
- data used in Fig. 1B), we used our model to estimate status quo detection times for the outbreaks.
  Because many recent outbreaks have been detected in healthcare settings<sup>59,69,71,72</sup>, we assumed
- 415 Because many recent outbreaks have been detected in healthcare settings<sup>59,69,71,72</sup>, we assumed 416 status quo detection was similar to hospital monitoring, except with a lower detection probability
- 410 status quo detection was similar to nospital monitoring, except with a lower detection probabilit 417 per case ( $p_{test}$ ) to reflect that symptomatic cases are less likely to be tested for a panel of
- 418 diseases without the proposed systematic, proactive testing scheme. The per-case detection
- 419 probability for status quo was set to 0.67 times that of hospital monitoring to match our modeled
- 420 status quo detection times for COVID-19 with those estimated independently  $by^{56}$  (Fig. 1B).
- 421 Data availability: Data are available in the supplement and at https://github.com/abliu/early 422 detection/releases.
- 423 **Code availability:** Code is available at https://github.com/abliu/early-detection/releases.

### 424 **References**

- 425 1. Kraemer, M. U. G. *et al.* The effect of human mobility and control measures on the
  426 COVID-19 epidemic in China. *Science* 368, 493–497 (2020).
- 427 2. Meyerowitz-Katz, G. *et al.* Is the cure really worse than the disease? The health impacts
  428 of lockdowns during COVID-19. *BMJ Global Health* 6, e006653 (2021).
- 429 3. Yamey, G. & Walensky, R. P. Covid-19: Re-opening universities is high risk. *BMJ* 370,
  430 m3365 (2020).
- 431 4. Brauner, J. M. *et al.* Inferring the effectiveness of government interventions against
  432 COVID-19. *Science* 371, eabd9338 (2021).
- 433 5. Ferguson, N. M. et al. Report 9 Impact of non-pharmaceutical interventions (NPIs) to 434 reduce COVID-19 mortality and healthcare demand.
- 435 https://www.imperial.ac.uk/medicine/departments/school-public-health/infectious-disease-
- 436 epidemiology/mrc-global-infectious-disease-analysis/covid-19/report-9-impact-of-npis-on-covid 437 19/ (2020).
- 438 6. Levine-Tiefenbrun, M. *et al.* SARS-CoV-2 RT-qPCR Test Detection Rates Are
- Associated with Patient Age, Sex, and Time since Diagnosis. *The Journal of Molecular Diagnostics* 24, 112–119 (2022).
- 441 7. Larremore, D. B. *et al.* Test sensitivity is secondary to frequency and turnaround time for
  442 COVID-19 screening. *Science Advances* eabd5393 (2020) doi:10.1126/sciadv.abd5393.
- 443 8. Liu, A. B. *et al.* Association of COVID-19 Quarantine Duration and Postquarantine 444 Transmission Risk in 4 University Cohorts. *JAMA Network Open* **5**, e220088 (2022).

- 445 9. Wyllie, A. L. *et al.* Saliva or Nasopharyngeal Swab Specimens for Detection of SARS446 CoV-2. *New England Journal of Medicine* 383, 1283–1286 (2020).
- 447 10. Yelin, I. *et al.* Evaluation of COVID-19 RT-qPCR Test in Multi sample Pools. *Clinical*448 *Infectious Diseases* 71, 2073–2078 (2020).
- 449 11. Karin, O. *et al.* Cyclic exit strategies to suppress COVID-19 and allow economic activity.
  450 (2020) doi:10.1101/2020.04.04.20053579.
- 451 12. Flaxman, S. *et al.* Estimating the effects of non-pharmaceutical interventions on COVID452 19 in Europe. *Nature* 584, 257–261 (2020).
- 453 13. Hatchett, R. J., Mecher, C. E. & Lipsitch, M. Public health interventions and epidemic
  454 intensity during the 1918 influenza pandemic. *Proceedings of the National Academy of Sciences*455 104, 7582–7587 (2007).
- 456 14. Peak, C. M., Childs, L. M., Grad, Y. H. & Buckee, C. O. Comparing nonpharmaceutical
- 457 interventions for containing emerging epidemics. *Proceedings of the National Academy of* 458 *Sciences* 114, 4023–4028 (2017).
- 459 15. Pei, S., Kandula, S. & Shaman, J. Differential effects of intervention timing on COVID460 19 spread in the United States. *Science Advances* 6, eabd6370 (2020).
- 461 16. Bureau of the Intergovernmental Negotiating Body, World Health Organization.
  462 *Conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at its*463 *third meeting*. 32 (2022).
- 464 17. Lander, E. & Sullivan, J. American Pandemic Preparedness: Transforming Our
  465 Capabilities. 27 (2021).
- 466 18. Botti-Lodovico, Y. *et al.* The Origins and Future of Sentinel: An Early-Warning System
  467 for Pandemic Preemption and Response. *Viruses* 13, 1605 (2021).
- 468 19. Ecker, D. J. How to Snuff Out the Next Pandemic. Scientific American Blog Network
  469 (2020).
- 470 20. Peccia, J. *et al.* Measurement of SARS-CoV-2 RNA in wastewater tracks community
  471 infection dynamics. *Nature Biotechnology* 38, 1164–1167 (2020).
- 472 21. The Nucleic Acid Observatory Consortium. A Global Nucleic Acid Observatory for
  473 Biodefense and Planetary Health. *arXiv:2108.02678 [q-bio]* (2021).
- 474 22. Hjelmsø, M. H. *et al.* Metagenomic analysis of viruses in toilet waste from long distance
  475 flights—A new procedure for global infectious disease surveillance. *PLOS ONE* 14, e0210368
  476 (2019).
- 477 23. Muntean, J., Howard, K. & Atwood, P. CDC has tested wastewater from aircraft amid
  478 concerns over Covid-19 surge in China. *CNN* (2023).

- 479 24. Nordahl Petersen, T. *et al.* Meta-genomic analysis of toilet waste from long distance
- 480 flights; a step towards global surveillance of infectious diseases and antimicrobial resistance.
- 481 Scientific Reports 5, 11444 (2015).
- 482 25. Mina, M. J. *et al.* A Global Immunological Observatory to meet a time of pandemics.
  483 *eLife* 9, e58989 (2020).
- 484 26. Chu, H. Y. *et al.* Early Detection of Covid-19 through a Citywide Pandemic Surveillance
  485 Platform. *New England Journal of Medicine* 383, 185–187 (2020).
- 486 27. Brownstein, J. S., Freifeld, C. C. & Madoff, L. C. Digital Disease Detection —
- Harnessing the Web for Public Health Surveillance. *The New England journal of medicine* 360,
  2153–2157 (2009).
- 489 28. Dugas, A. F. *et al.* Influenza Forecasting with Google Flu Trends. *PLOS ONE* 8, e56176
  490 (2013).
- 491 29. Bajema, N., Beaver, W. & Parthemore, C. *Toward a Global Pathogen Early Warning*
- 492 System: Building on the Landscape of Biosurveillance Today.
- https://councilonstrategicrisks.org/wp-content/uploads/2021/07/Toward-A-Global-Pathogen Early-Warning-System\_2021\_07\_20-1.pdf (2021).
- 495 30. Lee, V. J., Chiew, C. J. & Khong, W. X. Interrupting transmission of COVID-19:
  496 Lessons from containment efforts in Singapore. *Journal of Travel Medicine* 27, (2020).
- 497 31. Keshaviah, A. *et al.* Wastewater monitoring can anchor global disease surveillance
  498 systems. *The Lancet Global Health* 11, e976–e981 (2023).
- 499 32. Petros, B. A. *et al.* Multimodal surveillance of SARS-CoV-2 at a university enables
  500 development of a robust outbreak response framework. *Med* 0, (2022).
- 33. Boehm, A. B. *et al.* Regional Replacement of SARS-CoV-2 Variant Omicron BA.1 with
   BA.2 as Observed through Wastewater Surveillance. *Environmental Science & Technology* Letters 9, 575–580 (2022).
- 504 34. Kim, J. E., Lee, J. H., Lee, H., Moon, S. J. & Nam, E. W. COVID-19 screening center
  505 models in South Korea. *Journal of Public Health Policy* 42, 15–26 (2021).
- 506 35. Meakin, S. *et al.* Comparative assessment of methods for short-term forecasts of COVID507 19 hospital admissions in England at the local level. *BMC Medicine* 20, 86 (2022).
- 508 36. Arizti-Sanz, J. *et al.* Streamlined inactivation, amplification, and Cas13-based detection 509 of SARS-CoV-2. *Nature Communications* **11**, 5921 (2020).
- 510 37. Gregory, D. A., Wieberg, C. G., Wenzel, J., Lin, C.-H. & Johnson, M. C. Monitoring
- 511 SARS-CoV-2 Populations in Wastewater by Amplicon Sequencing and Using the Novel
- 512 Program SAM Refiner. Viruses 13, 1647 (2021).

- 513 38. Li, C. *et al.* Population Normalization in SARS-CoV-2 Wastewater-Based Epidemiology:
- 514 Implications from Statewide Wastewater Monitoring in Missouri. (2022)
- 515 doi:10.1101/2022.09.08.22279459.
- 516 39. Robinson, C. A. *et al.* Defining biological and biophysical properties of SARS-CoV-2 517 genetic material in wastewater. *Science of The Total Environment* **807**, 150786 (2022).
- 518 40. Bibby, K. & Peccia, J. Identification of Viral Pathogen Diversity in Sewage Sludge by 519 Metagenome Analysis. *Environmental Science & Technology* **47**, 1945–1951 (2013).
- 520 41. Creager, H. M. *et al.* Clinical evaluation of the BioFire® Respiratory Panel 2.1 and
  521 detection of SARS-CoV-2. *Journal of Clinical Virology* 129, 104538 (2020).
- 522 42. Edin, A., Eilers, H. & Allard, A. Evaluation of the Biofire Filmarray Pneumonia panel
  523 plus for lower respiratory tract infections. *Infectious Diseases* 52, 479–488 (2020).
- 524 43. Murphy, C. N. *et al.* Multicenter Evaluation of the BioFire FilmArray
- 525 Pneumonia/Pneumonia Plus Panel for Detection and Quantification of Agents of Lower
- 526 Respiratory Tract Infection. Journal of Clinical Microbiology 58, e00128–20 (2020).
- 44. Quick, J. *et al.* Multiplex PCR method for MinION and Illumina sequencing of Zika and
  other virus genomes directly from clinical samples. *Nature Protocols* 12, 1261–1276 (2017).
- 529 45. Ackerman, C. M. *et al.* Massively multiplexed nucleic acid detection with Cas13. *Nature*530 582, 277–282 (2020).
- 531 46. Chiu, C. Y. & Miller, S. A. Clinical metagenomics. *Nature Reviews Genetics* 20, 341–
   532 355 (2019).
- 533 47. Bar-On, Y. M., Sender, R., Flamholz, A. I., Phillips, R. & Milo, R. A quantitative 534 compendium of COVID-19 epidemiology. *arXiv:2006.01283 [q-bio]* (2020).
- 535 48. Du, Z. *et al.* Reproduction number of monkeypox in the early stage of the 2022 multi-536 country outbreak. *Journal of Travel Medicine* taac099 (2022) doi:10.1093/jtm/taac099.
- 537 49. U.S. Centers for Disease Control and Prevention (CDC). United States confirmed as
  538 country with circulating vaccine-derived poliovirus. *CDC* (2022).
- 539 50. Bradshaw, W. J., Alley, E. C., Huggins, J. H., Lloyd, A. L. & Esvelt, K. M. Bidirectional
  540 contact tracing could dramatically improve COVID-19 control. *Nature Communications* 12, 232
  541 (2021).
- 542 51. Hellewell, J. *et al.* Feasibility of controlling COVID-19 outbreaks by isolation of cases
  543 and contacts. *The Lancet Global Health* 8, e488–e496 (2020).
- 544 52. Lloyd-Smith, J. O., Schreiber, S. J., Kopp, P. E. & Getz, W. M. Superspreading and the 545 effect of individual variation on disease emergence. *Nature* **438**, 355–359 (2005).
- 546 53. Wu, F. *et al.* Wastewater surveillance of SARS-CoV-2 across 40 U.S. States from
  547 February to June 2020. *Water Research* 202, 117400 (2021).

- 548 54. Lu, F. S. *et al.* Estimating the cumulative incidence of COVID-19 in the United States
- 549 using influenza surveillance, virologic testing, and mortality data: Four complementary
- approaches. *PLOS Computational Biology* **17**, e1008994 (2021).
- 551 55. Abbott, S. *et al.* Epiforecasts/EpiNow2: 1.3.4 release. (2023)
- 552 doi:10.5281/zenodo.7611804.
- 553 56. Pekar, J. E. *et al.* The molecular epidemiology of multiple zoonotic origins of SARS-554 CoV-2. *Science* **377**, 960–966 (2022).
- 555 57. Massachusetts Water Resources Authority. MWRA Wastewater COVID-19 Tracking.556 (2022).
- 557 58. Adhikari, S. & Halden, R. U. Opportunities and limits of wastewater-based epidemiology
  558 for tracking global health and attainment of UN sustainable development goals. *Environment*559 *International* 163, 107217 (2022).
- 560 59. Sack, K., Fink, S., Belluck, P. & Nossiter, A. How Ebola Roared Back. *The New York* 561 *Times* (2014).
- 562 60. Brouwer, A. F. *et al.* Epidemiology of the silent polio outbreak in Rahat, Israel, based on
  563 modeling of environmental surveillance data. *Proceedings of the National Academy of Sciences*564 115, E10625–E10633 (2018).
- 565 61. Wu, F. *et al.* SARS-CoV-2 RNA concentrations in wastewater foreshadow dynamics and
  566 clinical presentation of new COVID-19 cases. *Science of The Total Environment* 805, 150121
  567 (2022).
- 568 62. Soller, J. *et al.* Modeling infection from SARS-CoV-2 wastewater concentrations:
  569 Promise, limitations, and future directions. *Journal of Water and Health* 20, 1197–1211 (2022).
- 570 63. Jones, D. L. *et al.* Shedding of SARS-CoV-2 in feces and urine and its potential role in 571 person-to-person transmission and the environment-based spread of COVID-19. *The Science of* 572 *the Total Environment* **749**, 141364 (2020).
- 573 64. Biobot Analytics. The Effect of Septic Systems on Wastewater-Based Epidemiology.
   574 http://biobot.io/wp-
- 575 content/uploads/2022/09/BIOBOT\_WHITEPAPER\_EFFECT\_OF\_SEPTIC\_V01-1.pdf (2022).
- 576 65. Mallela, A. *et al.* Bayesian Inference of State-Level COVID-19 Basic Reproduction
  577 Numbers across the United States. *Viruses* 14, 157 (2022).
- 578 66. Goldberg, C. Mass. Public Health Lab Can Now Test For New Coronavirus, Speeding
  579 Results. (2020).
- 580 67. Pekar, J., Worobey, M., Moshiri, N., Scheffler, K. & Wertheim, J. O. Timing the SARS581 CoV-2 index case in Hubei province. *Science* 372, 412–417 (2021).
- 582 68. Pekar, J. E. et al. Sars-cov-2-origins / multi-introduction. GitHub (2022).

583 69. Yuan, Yao, Yujie, Ma, Jialu, Zhou & Wenkun, Hou. Xinhua Headlines: Chinese doctor
584 recalls first encounter with mysterious virus - Xinhua English.news.cn. Xinhua (2020).

585 70. The 2019-nCoV Outbreak Joint Field Epidemiology Investigation Team & Li, Q. An
586 Outbreak of NCIP (2019-nCoV) Infection in China — Wuhan, Hubei Province, 2019–2020.
587 China CDC Weekly 2, 79–80 (2020).

588 71. Rosenthal, E. THE SARS EPIDEMIC: THE PATH; From China's Provinces, a Crafty
589 Germ Breaks Out. *The New York Times* (2003).

590 72. Garrett, L. The Coming Plague. (1994).

591 73. Center for Systems Science and Engineering (CSSE) at Johns Hopkins University.

592 COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns
 593 Hopkins University. (2022).

594 74. Mathieu, E. et al. Total COVID-19 tests per 1,000 people. Our World in Data (2020).

595 75. Harris, T. E. *The theory of branching processes*.

596 https://www.rand.org/content/dam/rand/pubs/reports/2009/R381.pdf (1964).

597 76. Yoo, S. J. *et al.* Frequent Detection of Pandemic (H1N1) 2009 Virus in Stools of 598 Hospitalized Patients. *Journal of Clinical Microbiology* **48**, 2314–2315 (2010).

599 77. Vetter, P. *et al.* Ebola Virus Shedding and Transmission: Review of Current Evidence.
 600 *The Journal of Infectious Diseases* 214, S177–S184 (2016).

601 78. Independent Evaluation Department, Asia Development Bank. *People's Republic of* 

602 *China: Wuhan Wastewater and Stormwater Management Project.* 

603 https://www.adb.org/sites/default/files/evaluation-document/188852/files/pvr-447.pdf (2016).

Faes, C. *et al.* Time between Symptom Onset, Hospitalisation and Recovery or Death:
Statistical Analysis of Belgian COVID-19 Patients. *International Journal of Environmental Research and Public Health* 17, 7560 (2020).

80. He, D. *et al.* Low dispersion in the infectiousness of COVID-19 cases implies difficulty
in control. *BMC Public Health* 20, 1558 (2020).

81. Wang, S. *et al.* Serial intervals and incubation periods of the monkeypox virus clades.
Journal of Travel Medicine taac105 (2022) doi:10.1093/jtm/taac105.

611 82. DeWitt, M. E. *et al.* Global monkeypox case hospitalisation rates: A rapid systematic
612 review and meta-analysis. *eClinicalMedicine* 54, 101710 (2022).

613 83. Reda, A., Hemmeda, L., Brakat, A. M., Sah, R. & El-Qushayri, A. E. The clinical

manifestations and severity of the 2022 monkeypox outbreak among 4080 patients. *Travel Medicine and Infectious Disease* 50, 102456 (2022).

84. Ryan, E. T., Hill, D. R., Solomon, T., Aronson, N. & Endy, T. P. *Hunter's Tropical Medicine and Emerging Infectious Diseases E-Book.* (Elsevier Health Sciences, 2019).

- 618 85. Mailhe, M. *et al.* Clinical characteristics of ambulatory and hospitalized patients with
- 619 monkeypox virus infection: An observational cohort study. *Clinical Microbiology and Infection* 620 (2022) doi:10.1016/j.cmi.2022.08.012.
- 621 86. Tiwari, A. *et al.* Monkeypox outbreak: Wastewater and environmental surveillance 622 perspective. *Science of The Total Environment* **856**, 159166 (2023).
- 623 87. Wolfe, M. K. *et al.* Detection of monkeypox viral DNA in a routine wastewater 624 monitoring program. (2022) doi:10.1101/2022.07.25.22278043.
- 88. U.S. Centers for Disease Control and Prevention (CDC) National Center for Health
  Statistics. Immunization. (2022).
- 627 89. World Health Organization. Circulating vaccine-derived poliovirus type 3 Israel.
  628 (2022).
- 629 90. Estivariz, Concepcion F., Link-Gelles, Ruth & Shimabukuro, Tom. Pinkbook:
  630 Poliomyelitis CDC. (2022).
- 631 91. Nelson, K. E. & Williams, C. M. Determinants of Epidemic Growth. In Chapter 6:
- Infectious Disease Dynamics. in *Infectious Disease Epidemiology: Theory and Practice* 135
  (Jones & Bartlett Learning, 2013).
- 634 92. Chung, P. W., Huang, Y. C., Chang, L. Y., Lin, T. Y. & Ning, H. C. Duration of
  635 enterovirus shedding in stool. *Journal of microbiology, immunology, and infection* 34, 167–170
  636 (2001).
- 637 93. Onorato, I. M. *et al.* Mucosal Immunity Induced by Enhanced-Potency Inactivated and
  638 Oral Polio Vaccines. *The Journal of Infectious Diseases* 163, 1–6 (1991).
- 639 94. Wong, Z. S. Y., Bui, C. M., Chughtai, A. A. & Macintyre, C. R. A systematic review of
- 640 early modelling studies of Ebola virus disease in West Africa. *Epidemiology & Infection* 145,
  641 1069–1094 (2017).
- 642 95. Drake, J. M. *et al.* Ebola Cases and Health System Demand in Liberia. *PLOS Biology* 13,
  643 e1002056 (2015).
- 644 96. Van Kerkhove, M. D., Bento, A. I., Mills, H. L., Ferguson, N. M. & Donnelly, C. A. A
  645 review of epidemiological parameters from Ebola outbreaks to inform early public health
  646 decision-making. *Scientific Data* 2, 150019 (2015).
- 647 97. Qureshi, A. I. *et al.* High Survival Rates and Associated Factors Among Ebola Virus
  648 Disease Patients Hospitalized at Donka National Hospital, Conakry, Guinea. *Journal of Vascular*649 *and Interventional Neurology* 8, S4–S11 (2015).
- 650 98. Fraser, C. *et al.* Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings.
  651 Science (New York, N.Y.) **324**, 1557–1561 (2009).

- 652 99. Heijnen, L. & Medema, G. Surveillance of Influenza A and the pandemic influenza A
  653 (H1N1) 2009 in sewage and surface water in the Netherlands. *Journal of Water and Health* 9,
- 654 434–442 (2011).
- 655 100. Presanis, A. M. *et al.* The Severity of Pandemic H1N1 Influenza in the United States,
  656 from April to July 2009: A Bayesian Analysis. *PLOS Medicine* 6, e1000207 (2009).
- Furuya-Kanamori, L. *et al.* Heterogeneous and Dynamic Prevalence of Asymptomatic
   Influenza Virus Infections. *Emerging Infectious Diseases* 22, 1052–1056 (2016).
- Lessler, J., Reich, N. G. & Cummings, D. A. T. Outbreak of 2009 Pandemic Influenza A
  (H1N1) at a New York City School. *New England Journal of Medicine* 361, 2628–2636 (2009).
- 103. Louie, J. K. *et al.* Factors Associated With Death or Hospitalization Due to Pandemic
  2009 Influenza A(H1N1) Infection in California. *JAMA* 302, 1896–1902 (2009).
- 663 104. Vynnycky, E. & White, R. An Introduction to Infectious Disease Modelling. (Oxford
  664 University Press, 2010).
- Morgan, D. *et al.* HIV-1 infection in rural Africa: Is there a difference in median time to
  AIDS and survival compared with that in industrialized countries? *AIDS (London, England)* 16,
  597–603 (2002).
- 106. Todd, J. *et al.* Time from HIV seroconversion to death: A collaborative analysis of eight
  studies in six low and middle-income countries before highly active antiretroviral therapy. *AIDS*(*London, England*) 21, S55 (2007).
- 671 107. CASCADE. Time from HIV-1 seroconversion to AIDS and death before widespread use
  672 of highly-active antiretroviral therapy: A collaborative re-analysis. Collaborative Group on AIDS
  673 Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action
  674 on SeroConversion to AIDS and Death in Europe. *Lancet (London, England)* 355, 1131–1137
  675 (2000).
- 676 108. Crum-Cianflone, N. F. HIV and the Gastrointestinal Tract. Infectious diseases in clinical
   677 practice (Baltimore, Md.) 18, 283–285 (2010).
- 678 109. Yolken, R. H., Li, S., Perman, J. & Viscidi, R. Persistent Diarrhea and Fecal Shedding of
- Retroviral Nucleic Acids in Children Infected with Human Immunodeficiency Virus. *The Journal of Infectious Diseases* 164, 61–66 (1991).
- 681 110. World Health Organization. Tuberculosis (TB). (2022).
- 682 111. Behr, M. A., Edelstein, P. H. & Ramakrishnan, L. Revisiting the timetable of
  683 tuberculosis. *The BMJ* 362, k2738 (2018).
- 684 112. Ma, Y., Horsburgh, C. R., White, L. F. & Jenkins, H. E. Quantifying TB transmission: A
- 685 systematic review of reproduction number and serial interval estimates for tuberculosis.
- 686 *Epidemiology and Infection* **146**, 1478–1494 (2018).

- 687 Acknowledgments: We gratefully acknowledge Mauricio Santillana, Nicholas B. Link, Fred S.
- Lu, and Andre T. Nguyen for sharing their estimates on COVID-19 incidence in the US states.
- 689 We also acknowledge Jonathan Pekar, Joel Wertheim, and Michael Worobey for sharing their
- 690 estimates on COVID-19 incidence in late 2019 and early 2020. We finally acknowledge Michael
- 691 McLaren, Becky Ward, and Quincey Justman for feedback on the manuscript.

#### 692 Funding:

- 693 Lynch Foundation Fellows Program in Systems Biology at Harvard Medical School (ABL)
- 694 National Library of Medicine grant T15LM007092 (DL)
- 695 National Institutes of Health grant R01GM120122 (APJ)
- 696 CDC contract 200-2016-91779 (WPH)
- 697 National Institutes of Health grant R01GM120122 (MS)
- This project has been funded (in part) by contract 200-2016-91779 with the Centers for Disease Control and Prevention.
- 700 Disclaimer: The findings, conclusions, and views expressed are those of the author(s) and do not
- necessarily represent the official position of the Centers for Disease Control and Prevention(CDC).
- 703 Author contributions:
- 704 Conceptualization: ABL, MS
- 705 Methodology: ABL, APJ, MS
- 706 Software: ABL
- 707 Validation: ABL
- 708 Formal analysis: ABL, DL
- 709 Investigation: ABL, DL
- 710 Resources: MS
- 711 Data Curation: ABL
- 712 Writing Original Draft: ABL, MS
- 713 Writing Review & Editing: ABL, DL, APJ, WPH, MS
- 714 Visualization: ABL, MS
- 715 Supervision: ABL, WPH, MS
- 716 Project administration: ABL, MS
- 717 Funding acquisition: MS

- 718 **Competing interests:** WPH is a member of the scientific advisory board and has stock options
- 719 in BioBot Analytics. MS is a cofounder of Rhinostics and consults for the diagnostic consulting
- 720 company Vectis Solutions LLC. The other authors declare that they have no competing interests.